Previewing Seven Phase 3 Obesity/Weight Loss Clinical Trials Set to Complete Soon in the United States

It is essential for clinicians to remain informed about clinical trial outcomes and resulting data that may inform therapeutic strategies, affect clinical guidelines, expand treatment options, and ultimately improve patient quality of life.

Today, we are previewing seven Phase 3 clinical trials focusing on obesity/weight loss that have anticipated completion dates that fall within now and the end of 2027. Of the seven clinical trials, one has not yet begun recruiting, but it has limited enrollment capacity and anticipates being completed by the end of the year. One trial is actively recruiting, and the remaining five are no longer recruiting. The trials featured below are arranged by start date.

Quick View Of Featured Clinical Trials

Phase 3 Clinical Trials

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) (EXER-MED)

• Sponsor: University of Virginia
• Goal: This clinical trial is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity.
• Interventions: Tizepatide, exercise
• Primary Outcome Measure: Weight
• Time Frame: Baseline and 16 weeks
• Study Details
• Source

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide (RENEW 1)

• Sponsor: Novo Nordisk A/S
• Goal: This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight.
• Interventions: Cagrilintide, placebo
• Primary Outcome Measures: Relative change in body weight; Number of participants with achievement of greater than or equals (>=) 5 percent (%) body weight reduction.
• Time Frames: From baseline (week 0) to end of treatment (week 64); From baseline (week 0) to end of treatment (week 64).
• Study Details
• Source

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (RENEW 2)

• Sponsor: Novo Nordisk A/S
• Goal: This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight.
• Interventions: Cagrilintide, placebo
• Primary Outcome Measures: Relative change in body weight; Number of participants with achievement of greater than or equals (>=) 5 percent (%) body weight reduction.
• Time Frames: From baseline (week 0) to end of treatment (week 64); From baseline (week 0) to end of treatment (week 64).
• Study Details
• Source

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

• Sponsor: Novo Nordisk A/S
• Goal: This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term.
• Interventions: CagriSema (Cagrilintide B and Semaglutide I), placebo
• Primary Outcome Measure: Relative change in body weight
• Time Frame: From baseline (week 0) to week 80
• Study Details
• Source

VK2735 for Weight Management Phase 3 (VANQUISH 1)

• Sponsor: Viking Therapeutics
• Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
• Interventions: VK2735
• Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment
• Time Frame: 78 weeks
• Study Details
• Source

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

• Sponsor: Viking Therapeutics
• Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight.
• Interventions: VK2735
• Primary Outcome Measure: Percent change in body weight from baseline to Week 78 in body weight
• Time Frame: 78 weeks
• Study Details
• Source

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

• Sponsor: Novo Nordisk A/S
• Goal: This study will look at how well CagriSema helps people with excess body weight lose weight.
• Interventions: Cagrilintide, semaglutide, placebo
• Primary Outcome Measures: Relative change in body weight; Achievement of ≥5% weight reduction.
• Time Frames: From baseline (week 0) to end of treatment (week 68); From baseline (week 0) to end of treatment (week 68).
• Study Details
• Source

Related Guidelines:

• Pharmacological Management of United States Adults with Overweight or Obesity
  • The Obesity Society (TOS), Obesity Medicine Association (OMA), Obesity Action Coalition (OAC), March 2026

• Management of Adult Overweight and Obesity
  • Veterans Health Administration / Department of Defense (VA/DOD), November 2025

Sign up for alerts and stay informed on the latest published guidelines.